In the last trading session, 1.05 million Cogent Biosciences Inc (NASDAQ:COGT) shares changed hands as the company’s beta touched 1.72. With the company’s per share price at $10.80 changed hands at -$0.1 or -0.92% during last session, the market valuation stood at $1.18B. COGT’s last price was a discount, traded about -12.41% off its 52-week high of $12.14. The share price had its 52-week low at $3.67, which suggests the last value was 66.02% up since then. When we look at Cogent Biosciences Inc’s average trading volume, we note the 10-day average is 0.91 million shares, with the 3-month average coming to 854.66K.
Analysts gave the Cogent Biosciences Inc (COGT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.36. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended COGT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Cogent Biosciences Inc’s EPS for the current quarter is expected to be -0.57.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cogent Biosciences Inc (NASDAQ:COGT) trade information
Instantly COGT was in red as seen at the end of in last trading. With action 1.41%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 83.67%, with the 5-day performance at 1.41% in the green. However, in the 30-day time frame, Cogent Biosciences Inc (NASDAQ:COGT) is 5.06% up. Looking at the short shares, we see there were 9.73 million shares sold at short interest cover period of 10.02 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18.5, meaning bulls need an upside of 41.62% from its current market value. According to analyst projections, COGT’s forecast low is 15 with 24 as the target high. To hit the forecast high, the stock’s price needs a -122.22% plunge from its current level, while the stock would need to soar -38.89% for it to hit the projected low.
Cogent Biosciences Inc (COGT) estimates and forecasts
Data shows that the Cogent Biosciences Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 56.52% over the past 6 months, a 7.02% in annual growth rate that is considerably lower than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 15.33%. The 2024 estimates are for Cogent Biosciences Inc earnings to increase by 4.15%.
COGT Dividends
Cogent Biosciences Inc is expected to release its next quarterly earnings report in November.
Cogent Biosciences Inc (NASDAQ:COGT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.12% of Cogent Biosciences Inc shares while 112.38% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.52%. There are 112.38% institutions holding the Cogent Biosciences Inc stock share, with POINT72 ASSET MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 10.5506% of the shares, roughly 10.47 million COGT shares worth $88.27 million.
COMMODORE CAPITAL LP holds the second largest percentage of outstanding shares, with 9.8126% or 9.74 million shares worth $82.09 million as of 2024-06-30.
